Figure 5
From: EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
Combined use of sorafenib and GSK126 or UNC1999 in liver cancer cells. (A) The combination index was calculated based on the data of the trypan blue dye exclusion test. (B) Cells treated with sorafenib and GSK126 or UNC1999 for 48 h were subjected to Western blot analyses. The arrow indicates the cleaved form of PARP. RI was shown as the means of three independent experiments.
